Lupin, Merck Serono partner to bring meds to emerging markets

MUMBAI — Lupin has entered into a long-term partnership with Merck Serono for the implementation of the company's general medicines portfolio expansion initiative in emerging markets, helping to fulfill local needs for affordable medications. The agreement could add up to 20 new products to the current portfolio, with the first launches expected to occur in 2016. 

 

The partnership will cover major markets like Brazil, Mexico and Indonesia, among other emerging markets, and will focus on cardiovascular and diabetes diseases. 

 

“The agreement with Lupin is an exciting new approach for Merck Serono to address local health needs in fast‐growing regions with constantly increasing demand for high quality medicines from trusted companies like Merck Serono and Lupin,” said Elcin Ergun, head of global commercial at Merck Serono. “The collaboration will significantly strengthen our portfolio and Merck Serono’s position as one of the major players in emerging markets, aiming to provide patients in these regions with better access to health.” 

 

Lupin will develop products, provide dossiers and supply finished products to Merck Serono. Merck Serono will be

the marketing authorization holder for the products, and will use its commercial and medical teams to bring these new medicines to customers. Financial terms of the transaction were not released.